RemeGen Co Ltd

688331

Company Profile

  • Business description

    RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

  • Contact

    58 Middle Beijing Road
    Yantai Area of Shandong Pilot Free Trade Zone
    Yantai Development Zone
    Yantai
    CHN

    T: +86 5353573511

    https://www.remegen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    3,070

Stocks News & Analysis

stocks

ChatGPT enters the retail space and one company surges

Investors cheer the ability to purchase directly from ChatGPT.
stocks

Alibaba fair value increases by 49%

Stronger-than-expected AI demand internationally and domestically.
stocks

Our fair value on ASX share falls by half

Downgrading our estimates due to lower growth.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,135.9019.50-0.21%
CAC 407,895.9415.070.19%
DAX 4023,880.72135.660.57%
Dow JONES (US)46,397.8981.820.18%
FTSE 1009,350.4350.590.54%
HKSE26,855.56232.680.87%
NASDAQ22,660.0168.860.30%
Nikkei 22544,932.63111.12-0.25%
NZX 50 Index13,292.36159.801.22%
S&P 5006,688.4627.250.41%
S&P/ASX 2008,848.8020.50-0.23%
SSE Composite Index3,882.7820.250.52%

Market Movers